Welcome to the UPF Digital Repository

Acute effects of 2C-E in humans: an observational study

Show simple item record

dc.contributor.author Papaseit Fontanet, Esther
dc.contributor.author Olesti Muñoz, Eulàlia, 1991-
dc.contributor.author Pérez Mañá, Clara
dc.contributor.author Torrens, Marta
dc.contributor.author Grifell Guardia, Marc
dc.contributor.author Ventura, Mireia
dc.contributor.author Pozo Mendoza, Óscar J., 1975-
dc.contributor.author de Sousa Fernandes Perna, Elizabeth B.
dc.contributor.author Ramaekers, Johannes G.
dc.contributor.author Torre Fornell, Rafael de la
dc.contributor.author Farré Albaladejo, Magí
dc.date.accessioned 2020-05-05T07:29:59Z
dc.date.available 2020-05-05T07:29:59Z
dc.date.issued 2020
dc.identifier.citation Papaseit E, Olesti E, Pérez-Mañá C, Torrens M, Grifell M, Ventura M, Pozo OJ, de Sousa Fernandes Perna EB, Ramaekers JG, de la Torre R, Farré M. Acute effects of 2C-E in humans: an observational study. Front Pharmacol. 2020; 11:233. DOI: 10.3389/fphar.2020.00233
dc.identifier.issn 1663-9812
dc.identifier.uri http://hdl.handle.net/10230/44402
dc.description.abstract 2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT2 A), 2B (5-HT2 B), and (5-HT2 C) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic effects, but its pharmacology in humans, including pharmacological effects and pharmacokinetics, have not yet studied. To assess the acute effects of 2C-E on physiological and subjective effects and evaluate its pharmacokinetics, an observational study was carried-out. Ten recreational users of psychedelics self-administered a single oral dose of 2C-E (6.5, 8, 10, 15, or 25 mg). Blood pressure and heart rate were evaluated at baseline, 2, 4, and 6 h post-administration. Three rating scales were administered to evaluate subjective effects: a set of Visual Analog Scales (VAS), the 49-item short form version of the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2, 4, and 6 h after self-administration. To assess 2C-E concentrations oral fluid (saliva) was collected during 6 h. 2C-E induced primarily alterations in perceptions, hallucinations, and euphoric-mood. Saliva maximal concentrations were achieved 2 h after self-administration. Administration of oral 2C-E at recreational doses produces a group of psychedelic-like effects such to 2C-B and other serotonin-acting drugs.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartof Front Pharmacol. 2020; 11:233
dc.rights © 2020 Papaseit, Olesti, Pérez-Mañá, Torrens, Grifell, Ventura, Pozo, de Sousa Fernandes Perna, Ramaekers, de la Torre and Farré. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Acute effects of 2C-E in humans: an observational study
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3389/fphar.2020.00233
dc.subject.keyword 2C-E (2; 5-Dimethoxy-4-ethylphenethylamine)
dc.subject.keyword Novel psychoactive substances (NPS)
dc.subject.keyword Phenylethylamines
dc.subject.keyword Psychedelic
dc.subject.keyword Psychostimulants
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking